Cisplatin

3:32
DNA damage repair mutations and poor chemotherapy response in bladder cancer
Yair Lotan
2:28
Defining platinum ineligibility in mUC
Shilpa Gupta
1:46
New promise in treating mBC: combining anti-AR therapy with chemotherapy
Shilpa Gupta
1:23
Nrf2 inhibitors to overcome chemoresistance
Simon Crabb
1:37
Radiosensitizers to increase radiotherapy efficacy
Ananya Choudhury
2:25
The continuing role of chemotherapy for bladder cancer
Ignacio Duran
3:23
Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors
Simon Crabb
2:47
Current treatment landscape of triple negative breast cancer
Adrian Harris
3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
3:28
Head and neck cancer challenges & cetuximab trial updates
Quynh-Thu Le
4:57
Cetuximab for oropharyngeal cancer: latest data from De-ESCALaTE
Hisham Mehanna
2:02
KEYNOTE-189: chemo plus pembrolizumab for NSCLC
Marina Garassino
2:38
The current treatment landscape for penile cancer
Lisa Pickering
2:34
Key trials that will affect the therapy landscape for NSCLC
Benjamin Besse
1:35
Cutting-edge UK trials for mesothelioma: double immuno, arginine depletion and molecular profiling
Dean Fennell
3:17
The development of immunotherapies in the treatment of relapsed metastatic head and neck cancer
Kevin Harrington
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals